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Abstract: Despite ample evidence that right ventricular function is a critical determinant of the clinical response to a 
spectrum of cardiovascular diseases, there has been only a limited analysis of the unique and distinguishing physiologic 
properties of the RV under normal circumstances and in response to pathologic insults. This review highlights some of 
these features and underscores the fact that rational therapy in RV failure should acknowledge this physiology and ought 
to be chamber specific. 
INTRODUCTION 
  Ever since the 17
th century, when Harvey first described 
the integrated nature of the circulation, there has been a clear 
recognition that right ventricular cardiac output (in the 
absence of intracardiac shunting) is equal to left ventricular 
cardiac output. Early cardiovascular investigators also recog-
nized that the RV was structurally, geometrically and 
mechanically distinct from the LV, and that its response to 
disease states was likewise quite different. Despite this, 
comparatively little attention has been paid to the basic 
physiology and biology of the RV (probably because it is not 
dramatically affected by the epidemic diseases of the 19
th 
and 20
th century) and the general assumption has been that 
the laws that define cardiac mechanics, and therapies that 
improve cardiac performance are equally applicable to the 
RV and the LV. This is only partly true.  
  Given the increasingly nuanced appreciation of the cell 
biology of cardiac (mal) adaptation as well as increasingly 
sophisticated biophysical and imaging tools, it seems as if a 
reexamination of the structure and function of the RV is now 
in order [1, 2]. Indeed, the NHLBI organized a working 
group in 2006 [3] in order to frame this discussion and this 
group identified a number of fertile areas for RV related 
translational research, including the distinguishing charac-
teristics of the right and left heart, the mechanism and role of 
right ventricular hypertrophy, the effect of pulmonary 
disease on RV function, and ultimately the design of 
therapeutic strategies tailored to RV disease. Thus, the goals 
of this paper are to review the current literature as it relates 
to normal RV physiology and the response of the RV to 
pathologic circumstances.  
I. THE NORMAL STRUCTURE AND FUNCTION OF 
THE RIGHT VENTRICLE 
  Anatomically the two most striking features of the right 
ventricle (relative to the left) is its complex shape which 
defies easy geometric approximation – it appears triangular 
when viewed from the side and crescentric when viewed in 
cross-section with a relatively thin free wall [4]. The muscle 
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fibers that comprise the RV have generally been charac-
terized as forming two layers – a superficial layer arranged 
circumferentially and parallel to the AV groove and a deep 
layer that is arranged longitudinally, from apex to base, a 
structure that allows only a limited range of contractile 
motion, predominately longitudinal shortening. This is in 
contrast to the far thicker fibers of the LV which are wrapped 
around the elliptical chamber in a more complex fashion – 
two anti-parallel muscular layers separated by a 
circumferential muscle band, which permits the complex 
motion of LV contraction, including torsion, shortening and 
thickening [4, 5]. The endocardial surface of the RV is 
generally more heavily trabeculated than the LV and a 
circumferential moderator band is often seen in its apical 
segment. A final and quite important feature of the RV 
relates to the anatomical structure of the tricuspid valve 
which has the largest annulus in the heart and is tethered by 
more than three papillary muscles [4, 6], features that 
conspire to make it a valve that is most vulnerable to 
structural deformation (for example in response to a 
sustained pressure or volume load).  
  Under normal circumstances, the RV is coupled to a low 
pressure, highly distensible pulmonary vascular tree. Conse-
quently right-sided pressures are lower than left-sided 
pressures and evidence an earlier systolic peak and more 
rapid pressure decline [7]. By virtue of the fact that the 
chamber thickness is far less and ventricular elastance is 
lower, the RV is far more afterload dependent than the LV 
[8, 9]. Very modest increases in pulmonary vascular resis-
tance (one component of afterload) may result in substantial 
declines in RV stroke volume. This has very substantial 
clinical implications (see below). The preload dependence of 
contraction (Frank-Starling Effect) which is quite clearly 
manifest in the LV is similarly evident in the RV through a 
physiologic range of filling pressures or in response to post-
extra-systolic potentiation (force-interval relationship) [10, 
11], however beyond these defined margins, the functional 
impact of increases in RV filling are more complicated to 
interpret. Excessive RV filling, for example, can result in a 
shift in septal orientation (reverse Bernheim effect or 
ventricular interdependence) and LV compression with 
subsequent impairment of ventricular performance [11]. 
Moreover, the pericardium likely imposes more constraint on 
the thin walled, more compliant, low-pressure right 
ventricular chamber than it does on the left ventricle [5]. Cardiac Resynchronization Therapy in Children  Current Cardiology Reviews, 2009, Vol. 5, No. 1    23 
Some of the hemodynamic properties of the RV (relative to 
the LV) are summarized in Table 1 (derived from [2]). 
  Energetically, the lower systolic pressure in the RV, and 
hence, the lower wall stress leads to lower O2 requirement 
compared to the LV both at rest and during exercise. 
Consistent with the lesser work of the RV, the resting RV 
coronary blood flow is lower than left coronary flow. 
Additionally, at rest, the RV extracts only ~50% of the O2 
supplied by the coronary flow whereas the LV extracts 
~75%. The lower coronary flow in the RV coupled with 
reduced O2 extraction provides both a flow reserve and a 
large O2 extraction reserve for the RV. In the LV, increases 
in O2 demand are primarily met by increased coronary flow 
[12, 13]. However, the RV can meet increases in O2 demands 
either through increases in coronary flow or by increased O2 
extraction [12, 13]. Interestingly, exercise-induced increases 
in RV O2 demand are met primarily by increases in O2 
extraction whereas increases in O2 demand induced by acute 
pulmonary hypertension are met primarily by increased 
coronary flow [14]. 
  Two other related factors that impact global RV 
dysfunction are worth comment: loss of atrial systole and 
loss of synchronicity. The former has been appreciated for 
many years and in fact maintenance of sinus rhythm is felt to 
be a key therapeutic maneuver in right ventricular infarction 
[15, 16]. A nice experimental demonstration is from the 
work of Mizobuchi et al. [17] who demonstrated a dispro-
portionate improvement in RV outflow track flow velocity 
relative to analogous measurements in the LV as a function 
of preserved atrial contraction. In general this phenomenon 
is felt to be reflective of enhanced compliance coupled with 
preserved length dependence of contraction. The app-
reciation of the importance of synchronous RV contraction is 
more recent and is derived from a few limited studies 
demonstrating that dual chamber pacing can dramatically 
improve RV dP/dt and cardiac index in patients with 
congenital heart disease, moderate RV dysfunction and right 
bundle branch block [18]. Whether this reflects a primary 
effect of the geometry of RV contraction, secondary effects 
on ventricular interdependence, or both is unclear.  
  The regulation of RV contractility, like that of the LV, is 
a function of heart rate, Frank-Starling mechanisms and 
autonomic input. As mentioned above, within the limits of 
normal filling pressures, heart rate and pre-load influences 
on RV function are not distinct from those of the LV, 
although once these limits are exceeded, factors such as 
pericardial constraint may play a role. In so far as autonomic 
input is concerned, there is a differential effect on function 
of the inflow and outflow regions and overall adrenergic and 
cholinergic receptor density is generally felt to be slightly 
higher in the RV than in the LV [19]. Vagal input tends to 
prolong the normal sequence of ventricular activation 
beginning with contraction of the inlet and ending with 
contraction of the infundibulum [5], thus enhancing mecha-
nical performance whereas beta adrenergic stimulation 
shortens the contraction time and may actually reverse this 
orderly contractile process. Some studies have suggested that 
alpha-adrenergic stimulation of the RV may have overall 
negative inotropic effects on the RV, in contrast to the well-
described positive inotropy seen in the LV [20]. In addition, 
there are data to suggest that the summed inotropic response 
of the infundibulum and outflow track may be greater than 
that in the inflow portion of the chamber [21, 22], raising the 
possibility that RV cardiac output may be compromised by 
outflow track obstruction during periods of catechol-
aminergic stress, especially when the chamber is underfilled. 
Cell Biology and Biochemical Properties of the Normal 
Right Ventricle  
  On the cellular level, few distinctions between right 
ventricular cardiomyocytes and left ventricular cardio-
myocytes have been described. However, there have been a 
number of reports showing that force generation of RV 
papillary muscle per unit mass is less than that of LV 
papillary muscle, although the shortening velocity of isolated 
RV muscle is greater than that of the LV [23, 24]. 
Additionally, isolated cell experiments comparing contractile 
properties of RV and LV myocytes have shown that 
maximal sarcomere shortening in RV myocytes was 
significantly less than in LV myocytes isolated from the 
same heart, while the diastolic sarcomere length was not 
different [25]. Measurements of intracellular calcium 
transients in isolated RV and LV myocytes show corres-
ponding differences; that is, the peak calcium transient in LV 
myocytes is significantly larger than in RV myocytes, sugg-
esting that calcium dynamics may be important in regulating 
the mechanical differences in these tissues. However, there 
are no interventricular differences in expression levels of the 
major calcium handling proteins in normal ventricles [25]. 
Table 1. Comparison of RV and LV Properties  
Properties RV  LV 
EDV, mL/m
2  75 ± 13(49-100)  65 ± 12 (44-90) 
Mass, g/m
2  26 ± 5 (17-34)  87 ± 12 (64-110) 
Wall thickness, mm   2-5  7-11 
Ventricular pressure, mmHg  25/4[(15-30)/(1-7)]  130/8 [(90-140)/(5-12)] 
Ventricular elastance mmHg/mL  1.30 ± .84  5.48 ± 1.23 
PVR versus SVR (dyne.s. cm
-5)  70 (20-130)  1100 (700-1600) 
Accommodation to imposed load  Better in response to volume overload  Better in response to pressure overload 24    Current Cardiology Reviews, 2009, Vol. 5, No. 1  Walker and Buttrick 
  It is possible that the difference in contractile velocities 
between the RV and the LV is, in part, due to differences in 
myosin heavy chain isozyme expression as it has been 
demonstrated that there is significantly more of the -myosin 
heavy chain (V1) isozyme (which is associated with a higher 
ATPase activity) in the RV compared to LV in both rats [23] 
and in rabbits [26]. It should be noted, though, that in the 
latter study, the Ca-ATPase activity was reduced in the RV 
compared to LV while shortening velocity was not mea-
sured. It is clear that the inherent differences in the extent 
and velocity of shortening between RV and LV cannot be 
explained solely by differences in myosin isozyme content 
and that further work is needed to sort this out. 
II. RIGHT VENTRICULAR FAILURE 
  When clinicians and cardiovascular researchers refer to 
“heart failure” they are invariably describing a symptom 
complex that is linked to impaired left ventricular perfor-
mance. This has been subcategorized as “ischemic” versus 
“dilated” and “systolic” versus “diastolic” and rarely is the 
function of the right ventricle commented on, except as it 
reflects collateral damage from left ventricular processes. 
This overall calculus is not completely inappropriate and in 
fact does reflect the incidence and prevalence of disease in 
western society. However it does not do justice to the facts 
that right ventricular dysfunction (in any setting) has 
profound prognostic significance and that the right ventricle 
evidences different biologic responses to complex pathologic 
loads than the LV so that therapy that is appropriate for LV 
dysfunction is not necessarily ideal for RV dysfunction.  
  The observation that right ventricular dysfunction is a 
strong and independent predictor of survival in the context of 
LV failure dates back to the early 1980s when Polak et al. 
[27] showed that survival of patients with NYHA II-IV 
symptoms was strongly and inversely correlated with RV 
ejection fraction (<35% RV EFx was associated with a 23% 
2 year survival vs. 71% with a normal RV, irrespective of 
LV EFx). This same finding was confirmed more recently by 
several other groups [28, 29] and has been extended to show 
correlations between pulmonary artery pressure, RV enlar-
gement and survival that are more strongly predictive than 
LV EFx [30-32]. Even in patients with biopsy proven 
myocarditis and left ventricular dysfunction, impaired right 
ventricular contractile indices, such as tricuspid annular 
systolic excursion, are associated with a greater likelihood of 
death or transplantation [33]. While the converse has not 
been demonstrated, namely that improvement in RV function 
in the context of LV dysfunction positively impacts 
prognosis, none the less it would seem to follow that an 
appreciation of the factors that contribute to RV dysfunction 
and of potential chamber specific therapy, is important and 
timely.  
  It is not our intention to comprehensively review the 
causes and mechanisms of right heart failure but rather to 
highlight some unifying principles that define the patho-
physiology of RV HF. However, it is worth outlining the 
spectrum of diseases that impact on right ventricular function 
in order to provide a framework for a more mechanistic 
overview. This is detailed in table 2, below, which provides 
a list of pathophysiologic categories rather than a comp-
rehensive list of disease entities. 
Response of the Right Ventricle to a Pathologic Load 
  The right ventricular response to a pathologic load is 
complex and reflects the nature, severity and chronicity of 
the insult. In addition, the timing of the insult (during 
neonatal, pediatric or adult life) is important and insults that 
are initiated early in life (such as congenital pulmonic 
stenosis) tend to be better tolerated than those imposed 
during adulthood. This is an interesting phenomenon and 
likely reflects the fact that the normal RV is relatively 
hypertrophic during fetal and neonatal life (RV and LV wall 
thickness and force development are equivalent in utero) and 
RV hypertrophy normally regresses during infancy as it 
accommodates to a lower resistance pulmonary circulation 
[34, 35]. When confronted with a persistent increase in 
pressure load such as is seen with congenital pulmonic 
stenosis, RVH persists which may help inure the chamber 
against afterload induced decompensation.  
  As mentioned above, the RV is generally felt to tolerate 
volume overload better than the LV. Mechanically this 
probably reflects improved muscle compliance and clinically 
is evidenced by the fact that RV systolic function remains 
well preserved even in the face of long-standing volume 
overload secondary to an atrial septal defect (ASD) or 
tricuspid regurgitation [36]. What eventually limits inte-
grated cardiovascular function in this context is ventricular 
interdependence with the associated shift in the interven-
tricular septum as well as increased pericardial constraint 
resulting in a reduction in LV cardiac output and diminished 
LV elastance, as well as the fact that overcirculation of the 
pulmonary vasculature may eventually translate into fixed 
pulmonary hypertension and an increase in RV afterload 
[36].  
Table 2. Selected Causes of RV Failure  
Pressure overload 
  LV failure (most common) 
  Transient pulmonary processes 
   Pulmonary  embolism 
    Pneumonia and other infiltrative diseases 
  Fixed pulmonary hypertension 
   Primary 
    Secondary (for example COPD) 
 Congenital  disease 
    Pulmonic stenosis (valvular, infundibular,  
   peripheral) 
   Systemic  RV 
Volume overload 
 Valvular  insufficiency 
    Tricuspid, either primary or acquired 
   Pulmonic 
 Congenital  disease 
    Atrial septal defect 
    Anomalous pulmonary venous return 
Intrinsic muscle disease 
  RV ischemia and/or infarction 
 Infiltrative  cardiomyopathy 
 Amyloid 
 Sarcoid 
 ARVD 
Impaired RV filling 
  Constrictive pericardial disease 
 Tricuspid  stenosis Cardiac Resynchronization Therapy in Children  Current Cardiology Reviews, 2009, Vol. 5, No. 1    25 
  In contrast, the adult RV appears to tolerate acute 
increases in afterload poorly. This was very nicely demons-
trated by MacNee et al. [9] (among others), who showed 
experimentally that an acute increase in pulmonary artery 
pressure of 20 mmHg resulted in a 30% decline in RV stroke 
volume whereas an analogous increase in LV afterload 
resulted in only a 10% decline in LV SV. Mechanistically 
this likely reflects the relatively thin wall of the RV as well 
as reduced elastance [37]. Moderate to severe acquired 
pulmonary hypertension usually results in RV dilation and 
failure and even modest elevations in acute pulmonary 
vascular resistance secondary to acute pulmonary emboliza-
tion can result in the inability of the RV to generate adequate 
systolic pressure and a precipitous fall in right ventricular 
stroke volume [38].  
Cell Biology of Right Ventricular Failure 
  Much of the early mechanical description of overall 
cardiac contractility was provided by examination of muscle 
preparations from the RV, since as described above, the RV 
is more highly trabeculated than the LV and working 
preparations were easier to obtain. Therefore, there is a fairly 
robust body of literature examining functional changes in the 
RV in different models of cardiac (both RV and LV) failure. 
However, not only is there still much controversy over the 
mechanism of the functional change in the failing myocyte, 
the nature of the functional change is still unclear. There are 
reports that in skinned fiber preparations from spontaneously 
hypertensive heart failure prone (SHHF) rats, the myofila-
ment function (force generated at a constant level of 
activator calcium) of RV trabeculae is reduced [39], inc-
reased [40], or unchanged [40], compared to control, depen-
ding on the stage of disease progression. In RV trabeculae 
from rats subjected to large LV infarctions with associated 
LV failure, there is a demonstrated decrease in RV 
myofilament function both in trabeculae [41] and in isolated 
skinned RV hypertrophic myocytes [42]. Similarly, it has 
recently been shown in intact RV strip preparations from rats 
subjected to large LV infarctions, that the force generated in 
the presence of either isoproterenol or calcium was markedly 
reduced [43].  
  It is well accepted that in cardiac myocytes, calcium 
regulates contraction by binding to the thin filament 
regulatory protein troponin C which in turn causes a confor-
mational shift in the other troponin subunits, troponin I and 
T, allowing myosin binding to actin, and in general, the 
velocity and strength of contraction are regulated by either 
changes in available calcium or by the calcium sensitivity of 
the contractile apparatus. There are undoubtedly differences 
in calcium handling in failing myocytes and as demonstrated 
by the changes in myofilament function in skinned 
preparations, and there are likely changes in the calcium 
sensitivity of the myofilaments.  
  In samples from the hypertrophic RV, correlations 
between expression levels (and/or post-translational modify-
cations) of numerous proteins and the degree of hypertrophy 
have recently been described [44]. The majority of the 
changes described have been in metabolic and stress-related 
proteins and likely reflect a shift from fatty-acid metabolism 
to an increase in glucose metabolism. Such metabolic shifts 
have been well described for various models of LV 
hypertrophy [45, 46], but are less well described in the RV 
[47]. However, the proteomic changes seen in the hyper-
trophied RV, including a decrease in -oxidation enzymes 
and an increase in glycolytic enzymes [44], would suggest 
that a similar shift in energy substrate utilization occurs in 
the hypertrophic RV as in the hypertrophic LV.  
Right Ventricular Response and Rational Therapy for 
Pulmonary Hypertension  
  While the most common cause of RV failure is LV 
failure, it is probably more instructive to dissect the RV 
response and therapeutic options available to treat RV 
decompensation in the setting of pulmonary hypertension. Of 
course many of the same principles hold for the treatment of 
combined RV and LV failure but the focus (appropriately) in 
this circumstance is on the LV. In pulmonary hypertension, 
the RV is primarily and predominantly affected so the 
physiology and therapy is more chamber specific.  
  While the classification of pulmonary hypertension is 
extensive and the pathogenesis is complex, none the less the 
unifying feature of the disease complex is that the RV is 
exposed to a progressive pressure load. While the initial 
adaptive response is myocardial hypertrophy (much like the 
LV when exposed to a pressure load), this is generally not 
adequate to normalize wall stress and progressive contractile 
dysfunction and chamber dilation occurs [48]. This is 
characterized by rising filling pressures, a decline in 
contractile indices, increased sphericity of the RV chamber 
(with likely loss of synchronous contraction), dilation of the 
tricuspid annulus with associated poor coaptation of the 
valve leaflets [8, 49, 50]. As a result, there is a functional 
tricuspid regurgitation and progressive volume overload of 
the RV. While this is functionally tolerated far better than 
pressure overload, the impact in this context is to amplify 
chamber dilation, increase ventricular wall stress, further 
impair indices of contractility and reduce right ventricular 
cardiac output. As the ventricle dilates, the ventricular 
interdependence becomes more pronounced and LV end-
diastolic dimension decreases and left-sided stroke volume 
falls [51]. Whether or not global ischemia also contributes to 
progressive declines in contractility is probably disease 
dependent, but it is worth noting that in general the RV is 
less vulnerable to ischemia than the LV [5]. While the 
severity of the pulmonary artery pressure is one of the more 
accessible measured parameters in pulmonary hypertension, 
right ventricular function is the most important determinant 
of survival (and as RV function declines and stroke volume 
falls, there may be a paradoxical decline in pulmonary artery 
pressure) [52, 53]. 
  Treatment of right ventricular dysfunction in this setting 
is largely empirical (and this review will not highlight 
pharmacologic advances that have clearly impacted on 
mortality) although an appreciation of right ventricular 
physiology would seem to support certain fundamental 
principles. First, since the primary insult is a pressure load 
with an associated increase in wall stress, a stimulus which is 
very poorly tolerated by the RV, afterload reduction is a 
primary therapy. A spectrum of vasodilators have been 
employed and it is quite clear that acute responsiveness to 
pulmonary vasodilators (regardless of class) has prognostic 
significance [54, 55]. Of the drugs studied, several, including 26    Current Cardiology Reviews, 2009, Vol. 5, No. 1  Walker and Buttrick 
endothelin receptor antagonists, such as bosentan, and 
phosphodiesterase 5 inhibitors, like sildenafil, appear to have 
independent beneficial effects of RV contractility beyond 
their effect on the pulmonary circulation [56, 57]. Moreover, 
it is clear that diminishing tricuspid regurgitation, reducing 
the volume load, and restoring synchronous contraction 
(with the secondary effect of improving ventricular 
interdependence) is equally important so progressive diuresis 
has obvious benefit. Conventional inotropes, such as 
dobutamine and milrinone (in normotensive RV failure) 
have been shown to be of use in acute right heart failure an 
effect which is mediated both by RV inotropy and also by 
virtue of their independent effect on pulmonary vascular 
resistance [58, 59]. 
  Therapies which are of obvious benefit in LV failure, 
such as beta-blockade and angiotensin converting enzyme 
inhibition have not demonstrated clinically significant 
benefit in RV failure and studies in animal models have 
suggested both a biologic basis for this as well as possible 
distinct targetable pathways. For example, Rouleau et al. 
[60] have shown, using a rabbit model of pulmonary artery 
banding, that RV failure results in a loss of inotropic 
responsiveness to Ang II and uncoupling of Ang I receptors. 
Studies that have suggested a benefit of beta-blocker therapy 
on RV function have all been done in the context of 
coincident LV failure so the independent impact on the RV 
has been difficult to assess [61]. In some models of pure RV 
failure, beta-blockers have proven to be deleterious, 
independent of their effect on pulmonary vasomotor tone 
although the biology underlying this is far from established 
[62, 63]. Fan et al. [63] have shown a decrease in beta-
adrenergic receptor density in the RV in response to chronic 
pressure overload (similar to that seen in LV failure) but 
there are no studies that have shown chronic beta-blocker 
therapy improves adrenergic responsiveness in the RV 
although elevated catecholamine levels may be associated 
with higher pulmonary vascular resistance [64]. It is also true 
that alpha adrenergic stimulation has differential effects on 
right and left ventricular trabeculae, and this biology might 
predict that beta-blockade would unmask the negative 
inotropic effects of alpha stimulation on the RV (in contrast 
to the positive inotropic effects on the LV) [20].  
  Given this, it is clear that the failing RV presents a 
qualitatively different substrate than the failing LV and 
pharmacotherapy should be tailored accordingly. 
  Maintenance of atrial systole and AV synchrony as well 
as synchronous RV contraction are also clearly important for 
the reasons articulated above and it is certainly true that 
progressive RV dilation secondary to a superimposed 
pressure load is commonly associated both with atrial 
arrhythmias and with the development of bundle branch 
block. In a large series of patients with surgically corrected 
congenital heart disease with RV involvement, such as 
Tetralogy of Fallot, Epsteins’s anomaly or those following a 
Fontan procedure, the incidence of atrial arrhythmia is ~50% 
[65] and in patients with mild-moderate acquired pulmonary 
hypertension, the incidence is ~10-15% in retrospective 
studies and is estimated to occur at a rate of 2-3% per year 
[15, 66]. Almost all studies report that the loss of atrial 
systole in these contexts results in acute clinical deterioration 
[15, 67]. Despite this there is no consensus as to how to 
maintain sinus rhythm and a number of approaches, 
including preemptive pacing and ablative remodeling of the 
right atrium have been proposed. As cited above, AV 
sequential (DOO) pacing, when asynchronous RV contrac-
tion is demonstrated, may have the dual benefit of 
maintaining atrial systole and preserving synchronous RV 
contraction [18, 68].  
CONCLUSIONS 
  In summary, two themes emerge: the first is that the right 
ventricle, by virtue of its geometry and its cell biology, 
behaves quite differently from the left ventricle, both in 
normal and pathologic circumstances, and the second is that 
deterioration of right ventricular function strongly predicts 
clinical outcomes in a variety of circumstances. Thus it is 
imprudent to ignore the RV any longer. Understanding its 
physiology and developing therapeutic strategies that are 
chamber specific will almost certainly have broad clinical 
benefit. 
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